Related Experiment Video
Updated: Mar 21, 2026
07:34
FISH for Pre-implantation Genetic Diagnosis
Published on: February 23, 2011
38.0K
Prenatal pharmacogenomics: a promising area for research
E H Dorfman1, E Y Cheng2,3, M F Hebert4
1Department of Biostatistics, University of Washington, Institute for Public Health Genetics, Seattle, WA, USA.
The Pharmacogenomics Journal
|May 12, 2016
Summary
Prenatal pharmacogenomic screening can reveal fetal genetic information about medication exposure and metabolism. This allows for optimized drug selection and dosage during pregnancy for improved fetal health outcomes.
Area of Science:
- Genetics
- Pharmacology
- Obstetrics
Background:
- Current prenatal genetic screening primarily targets fetal aneuploidy and genetic diseases.
- Emerging research indicates the fetal genome can provide insights into fetal exposures via placental transport and metabolism.
Purpose of the Study:
- To explore the clinical applications of prenatal pharmacogenomic screening.
- To highlight the potential for optimizing medication management and assessing fetal drug exposure risks.
Main Methods:
- Utilizes newly available noninvasive prenatal genetic screening methods.
- Focuses on analyzing fetal genotypes relevant to pharmacogenomics.
Main Results:
- Fetal genotypes can inform about placental transport and fetal metabolism of medications.
- Noninvasive methods enable access to fetal genetic data for obstetricians.
Conclusions:
- Prenatal pharmacogenomic screening offers prospective benefits for medication management.
- It also enables retrospective assessment of fetal drug exposure risks.
- This field warrants further research and clinical attention.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:29Pharmacogenetics and Pharmacogenomics: Overview
136
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
136
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
01:27Pharmacogenetics of Drug Metabolism: Overview
102
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
102
01:27Principles of Pharmacogenetics: Types of Genetic Variants
86
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
86
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
114
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
114